Abemaciclib was granted “breakthrough therapy designation” as a single agent for the treatment of patients with refractory hormone receptor-positive advanced or metastatic BC on the basis of the MONARCH 1 clinical trial results. The drug is currently being evaluated in two phase 3 trials in ...
Joint symptoms are a common side effect of aromatase inhibitors. However, it is not known if the risk of these symptoms varies between the members of this drug class. The aim of this study was to compare the frequency of joint symptoms associated with anastrozole and that associated with letr...
Avoid concomitant use of KISQALI FEMARA CO-PACK with strong CYP3A inhibitors and consider an alternative concomitant medication with less potential for CYP3A inhibition [seeDRUG INTERACTIONS]. If a strong CYP3A inhibitor must be coadministered, reduce the KISQALI dose to 400 mg once daily. If the ...
Orlistat, an anti-obesity drug approved by the U.S. FDA, has been used to improve or reverse the pathological characteristics of PCOS [20]. Kumar et al. found that orlistat in PCOS is as effective as metformin in reducing weight with improvement in the lipid profile and pregnancy rates [...
Conclusion: In the process of anti-cancer drug discovery, to find new potential anti-breast cancer agents, we designed and synthesized a novel series of letrozole analogs. Cytotoxicity evaluation revealed that compounds (1c) and (1 k) were the most potent compounds with comparative activity with...
01) within the fi rst month of letro zo le tr eatm ent .A 1l ho rm o nes returned to their respectiv e r ef- erence v alues 1 w eek after drug suspensio n.T esticular v olum e always remained below the reference value.The ejaculated sper— matozoa were cry oconserved ...